RxDoctor Payments Data

Frederick Weiland, MD

Nuclear Imaging & Therapy · Roseville, CANPI 1508805722

Payments from drug & device makers

What this record shows

3 manufacturers reported payments, led by Astellas Pharma US Inc at 54.3% of the total.

$332in general payments, 2019–2025

Across 4 payments — averaging $82.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$180
  • Pfizer$78
  • Alnylam Pharmaceuticals Inc.$73

What the payments were for

  • Food & beverage$15246%
  • Education$18054%

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few nuclear imaging & therapy providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$770,852
Medicare patients
4,954
Services billed
8,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear imaging & therapy in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →